Juventas Therapeutics to Present Top-Line Interim Results from Phase II STOP-HF Trial in Late-Breaking Oral Presentation at European Society of Cardiology Heart Failure Congress - kcentv.com - KCEN HD - Waco, Temple, and Killeen

Juventas Therapeutics to Present Top-Line Interim Results from Phase II STOP-HF Trial in Late-Breaking Oral Presentation at European Society of Cardiology Heart Failure Congress

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Juventas Therapeutics

CLEVELAND, May 6, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking oral presentation at the European Society of Cardiology Heart Failure Congress (ESC-HF) taking place May 17 – 20, 2014 in Athens, Greece.  The STOP-HF trial is a randomized, placebo-controlled, double-blinded study conducted at 15 centers in the United States to evaluate safety and efficacy of JVS-100 in patients with symptomatic ischemic cardiomyopathy.  Co-Principal Investigators for the trial are Drs. Warren Sherman, Director of Stem Cell and Regenerative Medicine, Cardiovascular Research Foundation, Columbia University Medical Center, Leslie Miller, Pepin Heart Institute, and Eugene Chung, Director of Heart Failure, the Ohio Heart and Vascular Center.

Juventas Therapeutics.

The STOP-HF study was designed to evaluate safety and efficacy of JVS-100 in patients with systolic heart failure of ischemic etiology.  Ninety-three patients were enrolled under the inclusion criteria of having an ejection fraction =40%, six-minute walk distance (6MWD) =400 meters and Minnesota Living with Heart Failure Questionnaire (MLHFQ) score =20 points.  Upon enrollment, patients were randomized to receive one of two JVS-100 doses or placebo.  The study drug was administered directly to the heart via the BioCardia Helical Infusion Catheter (HIC).

"The patients studied in STOP-HF comprise a population that are already on optimal medical therapy and whose heart failure is rapidly progressing," states Marc Penn, M.D., Ph.D., Founder and Chief Medical Officer for Juventas Therapeutics and Director of Cardiovascular Research at Summa Health System.  "JVS-100 has been shown in multiple pre-clinical and Phase I studies to slow or reverse disease progression.  We look forward to sharing our findings from this most recent Phase II study."

JVS-100 is a non-viral DNA plasmid that expresses human Stromal cell-Derived Factor 1 (SDF-1).  SDF-1 has been shown by several independent laboratories to improve cardiac function following a heart attack through recruiting endogenous stem cells to the damaged region, promoting new blood vessel growth and preventing ongoing-cell death.  In a Phase I study, Juventas previously demonstrated safety and preliminary clinical benefit for JVS-100 in patients with NYHA Class III heart failure.

Dr. Penn will present the STOP-HF four-month safety and efficacy results as a late-breaking clinical trial at ESC-HF on May 19, 2014.

"We are excited by the results from STOP-HF, which demonstrate for the first time in a randomized, double-blinded, placebo controlled trial that JVS-100 has therapeutic potential for patients with advanced heart failure," states Rahul Aras, Ph.D., President and CEO for Juventas Therapeutics.  "It is an honor to share these findings at a prominent international conference such as ESC-HF. We look forward to advancing our clinical study of this novel therapy." 

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, Ohio, is a privately held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to through mid-stage clinical trials for treatment of heart failure and critical limb ischemia.  Investors include Triathlon Medical Venture Partners, New Science Ventures, Fletcher Spaght Ventures, Takeda Ventures, Venture Investors, Early Stage Partners, Reservoir Venture Partners, and Cleveland Clinic.  The company has also received financial support through the Ohio Third Frontier-funded Global Cardiovascular Innovation Center, Center for Stem Cell & Regenerative Medicine and the National Center for Regenerative Medicine.

Logo - http://photos.prnewswire.com/prnh/20131028/DC04442LOGO

©2012 PR Newswire. All Rights Reserved.

  • Latest NewsMore>>

  • Court Strikes Down Federal Obamacare Subsidies

    Court Strikes Down Federal Obamacare Subsidies

    Tuesday, July 22 2014 11:11 AM EDT2014-07-22 15:11:14 GMT
    In a potentially lethal blow to Obamacare, a federal appeals court has ruled that the federal government may not subsidize health insurance plans bought by people in states that decided not to set up their own marketplaces under Obamacare.The law clearly says that states are to set up the exchanges. But 34 states opted not to, and the federal government took over in those states. The court ruled that federal government may not pay subsidies for insurance plans in those states."W...More >>
    In a potentially lethal blow to Obamacare, a federal appeals court has ruled that the federal government may not subsidize health insurance plans bought by people in states that decided not to set up their own marketplaces under Obamacare.The law clearly says that states are to set up the exchanges. But 34 states opted not to, and the federal government took over in those states. The court ruled that federal government may not pay subsidies for insurance plans in those states."W...More >>
  • Bracelet Honoring Deceased Soldiers Found At Belton Lake

    Bracelet Honoring Deceased Soldiers Found At Belton Lake

    Tuesday, July 22 2014 12:47 AM EDT2014-07-22 04:47:16 GMT
    (KCEN)—A bracelet honoring two soldier killed in Iraq is found at Belton Lake, and the man who discovered it is using social media to find its owner. Cory Self was in his truck Saturday night, about to head home after a day of fishing, when something in the road caught his eye. “I looked down and thought it was a piece of metal,” said Self. “I picked it up and realized that this is a pretty important bracelet for somebody.” Inscribed on the bracelet was PFC John Bishop and 1LT Timothy Cunning...More >>
    (KCEN)—A bracelet honoring two soldier killed in Iraq is found at Belton Lake, and the man who discovered it is using social media to find its owner. Cory Self was in his truck Saturday night, about to head home after a day of fishing, when something in the road caught his eye. “I looked down and thought it was a piece of metal,” said Self. “I picked it up and realized that this is a pretty important bracelet for somebody.” Inscribed on the bracelet was PFC John Bishop and 1LT Timothy Cunning...More >>
  • Johnny Manziel’s Jersey The No. 1 Seller At NFL’s online store

    Johnny Manziel’s Jersey The No. 1 Seller At NFL’s online store

    Monday, July 21 2014 11:53 PM EDT2014-07-22 03:53:34 GMT
    (NBC SPORTS) -- Time will tell if the Browns’ selection of quarterback Johnny Manziel works out, but this much appears true: from a merchandising standpoint, the move has been a home run thus far. According to the NFL, Manziel’s Cleveland jersey has outsold all other jerseys from April 1 through July 17 at the league’s online store, NFLShop.com. The sales of Manziel’s jersey are all the more impressive when you consider he wasn’t drafted until May 8. From there, it appears, sales have taken o...More >>
    (NBC SPORTS) -- Time will tell if the Browns’ selection of quarterback Johnny Manziel works out, but this much appears true: from a merchandising standpoint, the move has been a home run thus far. According to the NFL, Manziel’s Cleveland jersey has outsold all other jerseys from April 1 through July 17 at the league’s online store, NFLShop.com. The sales of Manziel’s jersey are all the more impressive when you consider he wasn’t drafted until May 8. From there, it appears, sales have taken o...More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KCEN. All Rights Reserved. Users of this site agree to the Terms of Service, Privacy Notice/Your California Privacy Rights, and Ad Choices.